Dry Powder Inhaler Devices Market Report - 2019 Medical Devices Pipeline Assessment - ResearchAndMarkets.com

DUBLIN--()--The "Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2019" report has been added to ResearchAndMarkets.com's offering.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Dry Powder Inhaler Devices pipeline products.

Scope

  • Extensive coverage of the Dry Powder Inhaler Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Dry Powder Inhaler Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Dry Powder Inhaler Devices Overview

3 Products under Development

3.1 Dry Powder Inhaler Devices - Pipeline Products by Stage of Development

3.2 Dry Powder Inhaler Devices - Pipeline Products by Territory

3.3 Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path

3.4 Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date

3.5 Dry Powder Inhaler Devices - Ongoing Clinical Trials

4 Dry Powder Inhaler Devices - Pipeline Products under Development by Companies

4.1 Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development

4.2 Dry Powder Inhaler Devices - Pipeline Products by Stage of Development

5 Dry Powder Inhaler Devices Companies and Product Overview

5.1 Acorda Therapeutics Inc Company Overview

5.2 Adamis Pharmaceuticals Corp Company Overview

5.3 Advent Pharmaceuticals Pty Ltd Company Overview

5.4 Aespira Ltd. Company Overview

5.5 AKELA Pharma Inc. (Inactive) Company Overview

5.6 AstraZeneca Plc Company Overview

5.7 Bayer AG Company Overview

5.8 Boehringer Ingelheim GmbH Company Overview

5.9 Circassia Pharmaceuticals Plc Company Overview

5.10 Eli Lilly and Co Company Overview

5.11 GlaxoSmithKline Plc Company Overview

5.12 Lupin Pharmaceuticals Inc Company Overview

5.13 MannKind Corp Company Overview

5.14 Monash University Company Overview

5.15 Nektar Therapeutics Company Overview

5.16 Ology Bioservices Inc Company Overview

5.17 OPKO Health Inc Company Overview

5.18 OtiTopic LLC Company Overview

5.19 Pharmaxis Ltd Company Overview

5.20 Respira Therapeutics Inc Company Overview

5.21 Sandoz International GmbH Company Overview

5.22 Sheffield Hallam University Company Overview

5.23 Spyryx Biosciences Inc Company Overview

5.24 Sun Pharma Advanced Research Company Ltd Company Overview

5.25 Teva Pharmaceutical Industries Ltd Company Overview

5.26 University of Kansas Company Overview

5.27 University of Sydney Company Overview

5.28 University of Texas Medical Branch at Galveston Company Overview

5.29 Vectura Group Plc Company Overview

5.30 Verona Pharma Plc Company Overview

5.31 Virginia Commonwealth University Company Overview

6 Dry Powder Inhaler Devices- Recent Developments

6.1 May 02, 2019: Teva reports first quarter 2019 financial results

6.2 May 01, 2019: GSK delivers sales of 7.7 billion +6% AER, +5% CER

6.3 Apr 25, 2019: 3M reports first-quarter 2019 results; company initiates restructuring

6.4 Apr 25, 2019: Orion Group Interim report January-March 2019

6.5 Apr 24, 2019: Novartis starts 2019 with strong sales and double digit core operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded

6.6 Apr 11, 2019: Fire at Orion's manufacturing plant in Turku

6.7 Apr 10, 2019: Teva signs new $2.3 billion syndicated revolving credit facility

6.8 Apr 09, 2019: Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off

6.9 Apr 02, 2019: Alcon announces Timothy Stonesifer as Chief Financial Officer

6.10 Apr 02, 2019: 3M Drug Delivery Systems relocates UK R&D to new, state-of-the-art facility

7 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/6f3zuu

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Medical Devices, Respiratory Drugs, Inhalers and Nebulisers, Respiratory Devices

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Medical Devices, Respiratory Drugs, Inhalers and Nebulisers, Respiratory Devices